Evidence map›Paper›PMID 36362348›Full record

ArticleInternational journal of molecular sciences2022

MK2 Promotes the Development and Progression of Pancreatic Neuroendocrine Tumors Mediated by Macrophages and Metabolomic Factors.

Damian Jacenik, Eric J Lebish, Ellen J Beswick

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Novel Therapeutic Targets for Tumor Microenvironment in Cancer.International journal of molecular sciences · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Damian JacenikDepartment of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.ORCID 0000-0003-4563-2303
Eric J LebishDivision of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.
Ellen J BeswickDivision of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.
University of Utah · US

Funding

G-CSF inhibition as a colorectal cancer therapyR01CA207051 · NCI · UNIVERSITY OF UTAH · PI BESWICK, ELLEN J. · 2016 to 2021
$1.7M
Foundation for Polish Science START 30.2021NCI NIH HHS R01 CA207051NCI NIH HHS R01CA207051
6 · The paper itself

Abstract

Cases of pancreatic neuroendocrine tumors (PNETs) are growing in number, and new treatment options are needed in order to improve patient outcomes. The mitogen-activated protein kinase-activated protein kinase 2 (MK2) is a crucial regulator of cytokine/chemokine production. The significance of MK2 expression and signaling pathway mediated by MK2 in PNETs has not been investigated. To characterize the impact of MK2 on PNET growth, we used the

Indexed as

Neuroectodermal Tumors, PrimitiveNeuroendocrine TumorsPancreatic NeoplasmsAnimalsChemokinesCytokinesDisease Models, AnimalMacrophagesMiceChemokinesCytokinesMAPKAPK2mitogen-activated protein kinase-activated protein kinase 2MK2neuroendocrine tumorpancreaspancreatic neuroendocrine tumor

Identifiers

PMID36362348
PMCPMC9658113
OpenAlexW4308522347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.